Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralizing antibodies for the prevention and treatment of COVID-19

8 Sept 2021

Abstract excerpt

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through the receptor-binding domain (RBD) in the S1 subunit of the viral spike (S) protein. This event is followed by virus-cell membrane fusion mediated by the S2 subunit, which allows virus entry into the host cell. Therefore, the SARS-CoV-2 S...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34497376
DOI: 10.1038/s41423-021-00752-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralizing antibodies for the prevention and treatment of COVID-19PMID 34497376Read ↗

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodiesSemantic proximity Read ↗

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.Semantic proximity Read ↗

Epitope classification and RBD binding properties of neutralizing antibodies against SARS-CoV-2 variants of concernSemantic proximity Read ↗

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy.Semantic proximity Read ↗

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinSemantic proximity Read ↗

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodiesSemantic proximity Read ↗

Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies.Semantic proximity Read ↗

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read ↗

Antibodies and Vaccines Target RBD of SARS-CoV-2Semantic proximity Read ↗

SARS-CoV-2 spike S2-specific neutralizing antibodiesSemantic proximity Read ↗

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read ↗

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.